Pharmathen is a research-oriented company aiming at the development of high quality pharmaceutical products both in the field of generics and innovative finished formulations. Pharmathen invests more than €20 million annually in Research and Development, developing 10-12 new generic molecules per year. In addition Pharmathen develops 3-4 projects of innovative formulations every year concerning mainly the development of advanced pharmaceutical and drug delivery technologies as well as their application in selected drug substances. With the application of innovative techniques and advanced technologies, Pharmathen aims to provide challenging solutions LCM of brand companies as well as to develop and establish new technology platforms and provide optimized pharmaceutical products to patients.

These activities are supported by two autonomous advanced laboratories in a 1200 m2 building in Pallini/Athens hosting a GLP/GMP compliant environment where lab-scale and pilot-scale development are conducted. Scaling-up is executed in collaboration with the Industrial Units following quality and process control strategies.

The intense R&D activity has resulted in Intellectual Property that in all cases is protected by patents (granted by European Patent Office, EPO and the United States Patent and Trademark Office, USPTO) and patent applications (PCT applications). Pharmathen currently holds 60 patents in its portfolio, whereas another 5 patent applications will be granted or submitted within the year.

Pharmathen R&D Dpt. is also actively involved in a number of research projects in collaboration with renowned Universities and Research Centers across the E.U., in order to investigate advanced and pioneering pharmaceutical technologies as well as their applicationon on an industrial scale.

The main research activities include:

  • Solubility / Permeability Enhancement Technologies
  • Alternative Pharmaceutical Dosage Forms
  • Modified Release Oral Formulations
  • Sustained Release Parenteral Depots – Long Acting Injectables